The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Congestive Heart Failure (CHF) Market Increase Between 2026 And 2030?
The congestive heart failure (CHF) market has experienced significant expansion in recent years. This market is set to increase from $17.1 billion in 2025 to $18.31 billion in 2026, registering a compound annual growth rate (CAGR) of 7.1%. The growth observed in prior periods can be attributed to an increasing aging population, the widespread prevalence of cardiovascular disease, restricted options for outpatient monitoring, numerous hospital readmissions, and a reliance on hospital-based care.
The congestive heart failure (CHF) market size is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $23.79 billion, advancing at a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this growth during the forecast period include the escalating prevalence of heart failure, enhanced diagnostic precision, the expansion of homecare environments, a growing uptake of guideline-driven treatments, and efforts aimed at decreasing hospital readmissions. Key trends expected during the same period encompass the increased use of combination drug treatments, a move towards managing heart failure in home settings, a greater emphasis on early detection and continuous monitoring, the development of chronic disease management initiatives, and the broadening of post-discharge care routes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp
What Are The Main Drivers Accelerating The Growth Of The Congestive Heart Failure (CHF) Market?
A rising number of individuals with cardiovascular conditions is projected to fuel the expansion of the congestive heart failure (CHF) market in the future. Cardiovascular pertains to the heart and blood vessels, highlighting their function in blood circulation and preserving the body’s general health. The increase in cardiovascular patients stems from factors such as inactive lifestyles, poor dietary habits, an aging populace, and urban development, necessitating more advanced healthcare and therapeutic options. Congestive heart failure (CHF) offers advantages for cardiovascular patients through specific interventions that boost cardiac efficiency, alleviate symptoms, and avert complications, thereby improving patient care and their general welfare. For example, data from the American College of Cardiology, a US-based nonprofit medical society, indicated that by January 2023, cardiovascular disease instances had climbed to 19.8 million in 2022. Furthermore, Eastern Europe records the highest death rate, standing at 553 deaths per 100,000. Consequently, the growing number of cardiovascular patients is spurring expansion within the congestive heart failure (CHF) market.
What Are The Core Segment Classifications In The Congestive Heart Failure (CHF) Market?
The congestive heart failure (chf) market covered in this report is segmented –
1) By Type: Systolic Heart Failure, Diastolic Heart Failure, Left-Sided Heart Failure, Right-Sided Heart Failure
2) By Treatment: Medication, Surgery
3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction
2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)
3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure
4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure
Which Trends Are Supporting The Evolution Of The Congestive Heart Failure (CHF) Market?
Leading companies in the congestive heart failure (CHF) market are concentrating on advanced innovations, such as single intracoronary infusion therapies, to deliver effective treatment options that improve heart function and enhance the quality of life for CHF patients. Single intracoronary infusion administers medication directly into the coronary artery, targeting the heart to provide precise treatment for conditions like congestive heart failure (CHF). For instance, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, commenced the GenePHIT Phase II trial for AB-1002, an investigational gene therapy aimed at congestive heart failure (CHF). This innovation employs a gene therapy approach to target non-ischemic cardiomyopathy, potentially offering a breakthrough in the treatment of CHF through advanced genetic solutions. The trial is designed as adaptive, double-blind, and placebo-controlled, intending to enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.
Which Industry Players Are Present In The Congestive Heart Failure (CHF) Market?
Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.
Access The Complete Congestive Heart Failure (CHF) Market Report:
https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report
Which Region Holds The Largest Share In The Congestive Heart Failure (CHF) Market?
North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (chf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Congestive Heart Failure (CHF) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp
Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2026, By The Business Research Company
Congenital Heart Defect Devices Global Market Report 2026
Cardiometabolic Diseases Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Pediatric Heart Valve Repair And Replacement Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
